Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will develop and commercialize the biosimilar form of Enbrel - HD203 - in all markets except Korea and Turkey, where Hanwha retained marketing rights.
You may also be interested in...
Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017
INCHEON, South Korea - Samsung Biologics entered the first stage of a plan to become a global biopharmaceutical company, breaking ground on a biologics manufacturing plant May 27. The company hopes to establish itself as a global contract manufacturer before entering the biosimilar sector with its first entrant, a biosimilar of the monoclonal antibody Rituxan (rituximab)